An­tibi­otics R&D takes an­oth­er hit as Achao­gen slash­es re­search ops in re­or­ga­ni­za­tion

There’s more bad news for the an­tibi­otics R&D field Thurs­day evening.

A few weeks af­ter the FDA green-light­ed Achao­gen’s $AKAO an­tibi­ot­ic Zem­dri (pla­zomicin) for uri­nary tract in­fec­tions but shunt­ed aside their ap­pli­ca­tion on blood­stream in­fec­tions, the biotech is lay­ing off rank-and-file re­searchers and let­ting go its top re­search ex­ecs.

Al­to­geth­er the com­pa­ny says it is cut­ting 80 jobs — 28% of the staff — as it chops spend­ing on ear­ly-stage re­search and de­vel­op­ment, tech­ni­cal op­er­a­tions and gen­er­al and ad­min­is­tra­tive ex­pens­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER